3 June 2010 -...“In the twelve months since the last AGM
Verona Pharma has seen significant progress in its drug development programmes.
“Highlights
- Successfully completed Phase I/IIa clinical trial of RPL554 and licensing discussions are progressing.
- Conducting further studies for RPL554 to add value to the licensing package and strategically prepare the drug for further clinical trials.
- VRP700 - regulatory documents have been finalised and awaiting submission to the appropriate regulatory and ethical authorities.
- NAIPs – continuing to evaluate novel compounds from collaborative partners, to determine clinical potential as anti-inflammatory drug candidates.
- Maintaining low burn rate, currently with approx. £3m in cash.
“Since successfully completing its Phase I/IIa clinical proof of concept trial of RPL554, leading to the issue of the quality assured report by the Centre for Human Drug Research ("CHDR"), discussions with potential licensing partners have been progressing. While discussions continue, we are adding value to the RPL554 licensing package by conducting further studies. Treatments for asthma and COPD are commonly delivered using a dry powder inhaler and we have conducted experimental studies to confirm that RPL554 can be administered in this form. In addition we are carrying out further clinical studies on the safety of RPL554 at higher doses, the duration of action with respect to bronchodilation, and the extent of its anti-inflammatory action. These additional studies are expected to increase the Company’s Intellectual Property package concerning RPL554; in turn strengthening our position during licensing discussions and increasing RPL554’s value...
[PDF] Verona Pharma's Press Release -
